Willow Biosciences Inc. (CANSF)
- Previous Close
0.0000 - Open
0.0785 - Bid 0.0650 x --
- Ask 0.0708 x --
- Day's Range
0.0785 - 0.0785 - 52 Week Range
0.0500 - 0.1050 - Volume
5,000 - Avg. Volume
39,039 - Market Cap (intraday)
11.392M - Beta (5Y Monthly) 1.12
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0400 - Earnings Date Nov 12, 2024 - Nov 18, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
2.00
Willow Biosciences Inc., a biotechnology company, develops, produces, and sells plant derived ingredients for consumer care, food and beverage, and pharmaceutical products in the United States. The company has a collaboration agreement with SUANFARMA to develop anti-infective API through precision fermentation; and a multi-product development and licensing partnership with Laurus Labs for manufacturing active pharmaceutical ingredients. Willow Biosciences Inc. was founded in 2019 and is headquartered in Calgary, Canada.
www.willowbio.com19
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: CANSF
View More
Performance Overview: CANSF
Trailing total returns as of 9/18/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CANSF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CANSF
View MoreValuation Measures
Market Cap
9.55M
Enterprise Value
10.41M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
7.38
Price/Book (mrq)
11.22
Enterprise Value/Revenue
7.69
Enterprise Value/EBITDA
-0.67
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-74.79%
Return on Equity (ttm)
-212.20%
Revenue (ttm)
1.84M
Net Income Avi to Common (ttm)
-8.7M
Diluted EPS (ttm)
-0.0400
Balance Sheet and Cash Flow
Total Cash (mrq)
1.02M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-3.34M
Research Analysis: CANSF
View MoreCompany Insights: CANSF
CANSF does not have Company Insights